Trial Profile
A Phase I/II Open Label, Multicenter Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company; Plexxikon
- 08 May 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 16 Apr 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2023.
- 25 Mar 2020 Planned End Date changed from 1 Feb 2020 to 1 Mar 2021.